Gilead Sciences (GILD) Stock Declines While Market Improves: Some Information for Investors

Gilead Sciences (GILD) closed the most recent trading day at $118.30, moving -2.71% from the previous trading session. The stock's change was less than the S&P 500's daily gain of 0.64%. Meanwhile, the Dow experienced a rise of 1.23%, and the technology-dominated Nasdaq saw an increase of 0.69%. Coming into today, shares of the HIV and hepatitis C drugmaker had gained 0.31% in the past month. In that same time, the Medical sector gained 0.63%, while the S&P 500 gained 0.55%. Analysts and investors alike will be keeping a close eye on the performance of Gilead Sciences in its upcoming earnings disclosure. The company is expected to report EPS of $1.86, down 2.11% from the prior-year quarter. At the same time, our most recent consensus estimate is projecting a revenue of $7.57 billion, reflecting a 0.05% fall from the equivalent quarter last year. For the annual period, the Zacks Consensus Estimates anticipate earnings of $8.17 per share and a revenue of $29.06 billion, signifying shifts of +76.84% and 0%, respectively, from the last year. Investors should also note any recent changes to analyst estimates for Gilead Sciences. These recent revisions tend to reflect the evolving nature of short-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research shows that these estimate changes are directly correlated with near-term stock prices. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.13% upward. Gilead Sciences is holding a Zacks Rank of #3 (Hold) right now. Looking at its valuation, Gilead Sciences is holding a Forward P/E ratio of 14.3. This signifies a discount in comparison to the average Forward P/E of 18.54 for its industry. Meanwhile, GILD's PEG ratio is currently 0.65. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Biomedical and Genetics industry currently had an average PEG ratio of 1.44 as of yesterday's close. The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 101, which puts it in the top 42% of all 250+ industries. The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Zacks' Research Chief Picks Stock Most Likely to "At Least Double"Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren’t winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%.See Our Top Stock to Double (Plus 4 Runners Up) >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Gilead Sciences, Inc. (GILD): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks